Article Text

PDF

Endralazine in patients with severe hypertension and renal insufficiency
  1. E. R. Higgs,
  2. R. A. Banks,
  3. P. R. Harrison,
  4. J. C. Kingswood,
  5. J. C. Mackenzie

    Abstract

    Endralazine, a new peripheral vasodilator, was given in conjunction with a beta-blocker to 21 patients with hypertension and chronic renal failure. All subjects were either poorly controlled on their previous antihypertensive regime or were experiencing unacceptable adverse effects from drugs. After 4 weeks blood pressure was reduced in all patients and symptomatic side effects were few. Two patients became anti-nuclear factor (ANF) positive in weak titre but without evidence of the lupus syndrome.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.